Litchlab, a leading CDMO specialized in next-generation drug delivery technologies, has officially launched its Drug-Loading Engineering Platform, a comprehensive, modular framework designed to solve the core challenge of loading therapeutic agents into delivery vehicles with high efficiency, stability, and clinical scalability.
In an era where biologics, RNA-based therapies, and precision oncology are redefining treatment paradigms, drug delivery systems must go beyond mere encapsulation—they must engineer function. Litchlab’s platform provides a robust, validated approach for tuning drug-to-carrier interactions, enhancing payload stability, and achieving customizable release kinetics for a broad spectrum of molecules and diseases.
Litchlab's Drug-Loading Engineering Platform integrates a material-based design system with payload-optimized techniques, covering:
Liposomes: including PEGylated, pH-sensitive, cationic liposomes
Polymeric Nanoparticles: PLA, PLGA, PCL-based particles with EPR tuning
Micelles: block copolymer micelles (PEG-PLA, PEG-PCL) with core-loading optimization
Hydrogels: in situ gelling or injectable systems for depot delivery
Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)
Hybrid & Smart Systems: combining polymers + lipids or stimuli-responsive features
Small Molecules (e.g., poorly soluble anticancer agents like paclitaxel, docetaxel)
Peptides & Proteins (e.g., insulin, interferons, enzymes)
Monoclonal Antibodies (mAbs) and Antibody Fragments
siRNA, mRNA, and CRISPR components (electrostatically complexed or encapsulated)
ADC Hydrophobic Payloads (e.g., MMAE, DM1)
Vaccines (antigens + adjuvant combinations)
| Feature | Description |
|---|---|
| Multi-technique Loading | Ultrasonication, ethanol injection, thin-film hydration, double emulsion, nanoprecipitation, electrospray |
| High Encapsulation Efficiency | 80–95% for small molecules, >90% for siRNA via ionizable lipid systems |
| Controlled Release | Sustained release from 24h to 6 weeks, tailored via matrix properties |
| Surface Engineering | Ligand conjugation for active targeting (e.g., folate, RGD peptides, aptamers) |
| Dual-Loading Capabilities | Core + shell payload strategy for combination therapies (e.g., chemo + immunomodulator) |
| Stability Optimization | Lyophilization support, cryoprotectant screening, and accelerated stability under ICH Q1A(R2) |
The drug delivery market is evolving under three global forces:
Rising complexity of APIs (e.g., biologics, RNA, hydrophobic payloads)
Demand for long-acting formulations (e.g., depot injections, ocular/oncology implants)
Integration of CDMO + formulation innovation to reduce time-to-clinic
| Therapeutic Area | Project Highlight |
|---|---|
| Oncology | Liposomal paclitaxel with folate targeting — 92% loading, pH-sensitive release |
| Neurodegenerative | PEG-PCL micelles for BBB-penetrant delivery of donepezil |
| Ophthalmology | Thermosensitive hydrogel for anti-VEGF peptide delivery to the posterior eye |
| Infectious Diseases | SLNs co-loaded with antibiotic and immunomodulator for resistant strains |
| Vaccinology | mRNA-loaded lipid hydrogel depot with immunogenicity extended beyond 60 days |
Formulation Development & QbD Optimization
Small Scale Feasibility → GMP Scale-Up (1g to 10+ kg)
Sterile Manufacturing: Liquid, Lyophilized, Injectable
ICH-compliant Stability Studies (real-time & accelerated)
Regulatory Support for IND, IMPD, NDA submissions (FDA, EMA, NMPA)
Whether your program demands high drug load, long-term stability, or dual-drug co-delivery, Litchlab provides the scientific know-how, scalable infrastructure, and regulatory insight to turn drug delivery innovation into clinical success.
Contact: sales@litchlab.com
Contact: RD2@litchlab.com
Website: www.litchlab.com
